Results for tag: "Xgeva"

Xgeva (denosumab) is a monoclonal antibody used to treat bone metastases in patients with solid tumors. It is used to prevent skeletal-related events (SREs) such as fractures, spinal cord compression, and the need for radiation or surgery to the bone. Xgeva is approved for use in adults and adolescents with bone metastases from solid tumors, including breast, prostate, and lung cancer. It is also approved for the prevention of skeletal-related events in adults with multiple myeloma. Xgeva is administered as an intravenous (IV) infusion every four weeks. It works by blocking the activity of a protein called RANKL, which is involved in the formation and breakdown of bone. By blocking RANKL, Xgeva helps to reduce the risk of SREs in patients with bone metastases. Xgeva is marketed by Amgen, a biotechnology company based in the United States. Other companies in the market include Novartis, Merck, and Pfizer. Show Less Read more